FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385294580> ?p ?o ?g. }

• W4385294580 endingPage "e767" @default.
• W4385294580 startingPage "e764" @default.
• W4385294580 abstract "Background: Therapy options for relapsed/refractory acute myelogenous leukemia (AML) are limited. Palliative chemotherapy options have been explored in adult patients, but little evidence exists in children. Objectives: Describe the clinical course of 2 pediatric patients with refractory AML who transitioned to outpatient palliative chemotherapy with good disease control and quality of life on these regimens. Patients and Methods: Patient 1 was a 2-year-old girl who received a total of 4 cycles of standard chemotherapy with multiple complications and 15% to 20% blasts on marrow subsequent evaluation. An outpatient regimen of decitabine and vorinostat was consequently chosen for her. Patient 2 was a 16-year-old boy with residual disease after induction 1 with arm A with cytarabine, daunorubicin, and etoposide. His induction 2 course was complicated by multiorgan failure secondary to multiple infections including Klebsiella pneumonia and radiographically identified pulmonary fungal disease. On recovery, the marrow showed no disease but after the toxicities of initial therapy, the patient pursued a palliative regimen with azacitidine and lenalidomide. Results: Patient 1 tolerated her regimen for 14 months, requiring weekly blood products and only one hospitalization for a central-line infection. Her blast count then increased precipitously, the disease progressed, and she died comfortably while receiving hospital-based end-of-life care. Patient 2 tolerated 14 months of his regimen. On a surveillance marrow sample, he was found to have 0.02% minimal residual disease. He then elected to pursue marrow transplantation. He maintained remission until his 6-month posttransplant surveillance bone marrow biopsy, which revealed 0.04% minimal residual disease. Conclusion: We describe 2 pediatric patients with relapsed/refractory AML who achieved disease control and acceptable quality of life utilizing outpatient palliative chemotherapy for over 12 months. These regimens should be considered in patients who no longer desire cytotoxic chemotherapy or are ineligible for further aggressive approaches." @default.
• W4385294580 created "2023-07-28" @default.
• W4385294580 creator A5000815645 @default.
• W4385294580 creator A5005769784 @default.
• W4385294580 creator A5021102277 @default.
• W4385294580 creator A5033355944 @default.
• W4385294580 creator A5068398828 @default.
• W4385294580 date "2023-07-03" @default.
• W4385294580 modified "2023-10-16" @default.
• W4385294580 title "Prolonged Survival Using Outpatient Palliative Chemotherapy in Two Children With Refractory Acute Myelogenous Leukemia" @default.
• W4385294580 cites W1920222387 @default.
• W4385294580 cites W1963919702 @default.
• W4385294580 cites W1988907854 @default.
• W4385294580 cites W2017224680 @default.
• W4385294580 cites W2040852160 @default.
• W4385294580 cites W2905325447 @default.
• W4385294580 cites W3046395109 @default.
• W4385294580 cites W3083003645 @default.
• W4385294580 cites W3117581628 @default.
• W4385294580 doi "https://doi.org/10.1097/mph.0000000000002704" @default.
• W4385294580 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37494613" @default.
• W4385294580 hasPublicationYear "2023" @default.
• W4385294580 type Work @default.
• W4385294580 citedByCount "0" @default.
• W4385294580 crossrefType "journal-article" @default.
• W4385294580 hasAuthorship W4385294580A5000815645 @default.
• W4385294580 hasAuthorship W4385294580A5005769784 @default.
• W4385294580 hasAuthorship W4385294580A5021102277 @default.
• W4385294580 hasAuthorship W4385294580A5033355944 @default.
• W4385294580 hasAuthorship W4385294580A5068398828 @default.
• W4385294580 hasConcept C126322002 @default.
• W4385294580 hasConcept C141071460 @default.
• W4385294580 hasConcept C159110408 @default.
• W4385294580 hasConcept C2776694085 @default.
• W4385294580 hasConcept C2778041864 @default.
• W4385294580 hasConcept C2778119113 @default.
• W4385294580 hasConcept C2778461978 @default.
• W4385294580 hasConcept C2781413609 @default.
• W4385294580 hasConcept C2994186709 @default.
• W4385294580 hasConcept C3020110884 @default.
• W4385294580 hasConcept C71924100 @default.
• W4385294580 hasConceptScore W4385294580C126322002 @default.
• W4385294580 hasConceptScore W4385294580C141071460 @default.
• W4385294580 hasConceptScore W4385294580C159110408 @default.
• W4385294580 hasConceptScore W4385294580C2776694085 @default.
• W4385294580 hasConceptScore W4385294580C2778041864 @default.
• W4385294580 hasConceptScore W4385294580C2778119113 @default.
• W4385294580 hasConceptScore W4385294580C2778461978 @default.
• W4385294580 hasConceptScore W4385294580C2781413609 @default.
• W4385294580 hasConceptScore W4385294580C2994186709 @default.
• W4385294580 hasConceptScore W4385294580C3020110884 @default.
• W4385294580 hasConceptScore W4385294580C71924100 @default.
• W4385294580 hasIssue "6" @default.
• W4385294580 hasLocation W43852945801 @default.
• W4385294580 hasLocation W43852945802 @default.
• W4385294580 hasOpenAccess W4385294580 @default.
• W4385294580 hasPrimaryLocation W43852945801 @default.
• W4385294580 hasRelatedWork W1509346046 @default.
• W4385294580 hasRelatedWork W1904016001 @default.
• W4385294580 hasRelatedWork W2073730465 @default.
• W4385294580 hasRelatedWork W2077980843 @default.
• W4385294580 hasRelatedWork W2086955530 @default.
• W4385294580 hasRelatedWork W2113871094 @default.
• W4385294580 hasRelatedWork W2377520785 @default.
• W4385294580 hasRelatedWork W2387113950 @default.
• W4385294580 hasRelatedWork W2414858770 @default.
• W4385294580 hasRelatedWork W2417697013 @default.
• W4385294580 hasVolume "45" @default.
• W4385294580 isParatext "false" @default.
• W4385294580 isRetracted "false" @default.
• W4385294580 workType "article" @default.